Denigma Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Memantine HCl

Indications/Uses

Moderate to severe Alzheimer's disease.

Click to view Denigma detailed prescribing information

Dosage/Direction for Use

Adult Dose titration: Wk 1: 5 mg once & at the same time daily for 7 days. Wk 2: 10 mg once & at the same time daily for 7 days. Wk 3: 15 mg once & at the same time daily for 7 days. Wk 4: 20 mg once & at the same time daily for 7 days. Max: 20 mg daily. Maintenance: 20 mg daily. Elderly >65 yr 20 mg once daily. Renal impairment: CrCl 30-49 mL/min 10 mg daily, may be increased up to 20 mg daily if well tolerated after 7 days, 5-29 mL/min 10 mg daily.

Click to view Denigma detailed prescribing information

Overdosage

View Denigma overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: Take at the same time each day.

Contraindications

Hypersensitivity.

Click to view Denigma detailed prescribing information

Special Precautions

Patients w/ epilepsy, history of convulsion or predisposing factors for epilepsy. Avoid concomitant use of other N-methyl-D-aspartate (NMDA)-antagonists, eg, amantadine, ketamine or dextromethorphan. Carefully monitor patient whose urine pH may be increased by factors eg, drastic changes in diet, massive indigestion of alkalising gastric buffers; renal tubulary acidosis, severe UTI w/ proteus bacteria. Closely supervise patients w/ recent MI, uncompensated CHF (NYHA III-IV), or uncontrolled HTN. May affect ability to drive or operate machinery. Not recommended in patients w/ severe hepatic impairment. Pregnancy. Do not breastfeed during therapy. Paed patients.

Click to view Denigma detailed prescribing information

Use In Pregnancy & Lactation

Click to view Denigma detailed prescribing information

Adverse Reactions

Drug hypersensitivity; somnolence; dizziness, balance disorders; HTN; dyspnoea; constipation; elevated liver functions test; headache.

Click to view Denigma detailed prescribing information

Drug Interactions

May enhance effects of L-dopa, dopaminergic agonists & anticholinergics. May reduce effects of barbiturates & neuroleptics. May modify effects of antispasmodics, dantrolene or baclofen; dosage adjustment may be necessary. Risk of pharmacotoxic psychosis w/ amantadine, ketamine & dextromethorphan & possibly phenytoin. Potential risk of increased plasma levels of cimetidine, ranitidine, procainamide, quinidine, quinine & nicotine. May reduce serum level of hydrochlorothiazide. Close monitoring of prothrombin time or INR in patients concomitantly treated w/ oral anticoagulants.

Click to view Denigma detailed prescribing information

Storage

View Denigma storage conditions for details to ensure optimal shelf-life.

Description

View Denigma description for details of the chemical structure and excipients (inactive components).

Action

View Denigma mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Neurodegenerative Disease Drugs

ATC Classification

N06DX01 - memantine ; Belongs to the class of other anti-dementia drugs.

Regulatory Classification

POM

Presentation/Packing

Form

Denigma FC tab 10 mg

Packing/Price

2 × 14's

Denigma

memantine

Manufacturer:

Kusum

Distributor:

JDS